<DOC>
	<DOCNO>NCT02163915</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability TAK-137 administer multiple oral dos adult attention-deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Multiple Rising Doses TAK-137 Adults With Attention-Deficit/Hyperactivity Disorder .</brief_title>
	<detailed_description>The drug test study call TAK-137 . TAK-137 test find safe well-tolerated dose assess TAK-137 metabolized people attention-deficit/ hyperactivity disorder ( ADHD ) . This study look side effect lab result people take TAK-137 . This study design randomize , sequential-cohort , multiple rise dose study . Therefore , TAK-137 2 mg Cohort start TAK-137 0.5 mg Cohort complete , etc . This trial conduct United States . The overall time participate study 42 day . Participants make least 2 visit clinic , include one 9-day period confinement clinic . All participant contact telephone 7 day last dose study drug follow-up assessment . A decision make terminate study emerge data preclinical study could assess .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Is male female adult 18 55 year age , inclusive . 2 . Weighs least 45 kg body mass index ( BMI ) 18 30.0 kg/m^2 , inclusive Screening . 3 . Has document diagnosis attentiondeficit/hyperactivity disorder ( ADHD ) minimum 1 year . 4 . Is willing discontinue medication treat adult ADHD ( eg , stimulant , antidepressant ) medication dietary product specify protocol , Day 7 Followup phone call ( Day 14 ) . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has uncontrolled , clinically significant neurologic ( include mildly abnormal significantly abnormal EEG screening ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder ( ADHD ) , abnormality , may impact ability participant participate potentially confound study result . 3 . Has previously seizure convulsion ( lifetime ) , include absence seizure febrile convulsion . 4 . Has positive urine drug result drug abuse amphetamine medication treat ADHD positive result alcohol Screening Checkin ( Day 1 ) . 5 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products . 6 . Is pregnant lactate intend become pregnant , , within 12 week participate study ; intend donate ova time period . 7 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>